Clinical Trial Detail

NCT ID NCT04267848
Title Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Gemcitabine

Carboplatin + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Cisplatin + Gemcitabine + Pembrolizumab

Carboplatin + Paclitaxel

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST